TY - JOUR
T1 - Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
T2 - Current Status and Future Directions
AU - Bhalla, Sheena
AU - Doroshow, Deborah Blythe
AU - Hirsch, Fred R.
N1 - Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2020/11
Y1 - 2020/11
N2 - Immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigm for advanced non-small cell lung cancer (NSCLC). Although certain patients achieve significant, long-lasting responses from checkpoint blockade, the majority of patients with NSCLC do not and may be unnecessarily exposed to inadequate therapies and immune-related toxicities. Therefore, there is a critical need to identify biomarkers predictive of immunotherapy response. While tumor and immune cell expression of programmed death ligand-1 and, more recently, tumor mutational burden are used in clinical practice and may correlate with immunotherapy response in selected circumstances, neither consistently predicts an individual patient's likelihood of clinical benefit from ICI therapy. More recently, innovative approaches such as blood-based assays and combination biomarker strategies are under active investigation. This review will focus on the current role and challenges of programmed death ligand-1 and tumor mutational burden as predictive biomarkers for immunotherapy response in advanced NSCLC and explore promising novel biomarker strategies.
AB - Immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigm for advanced non-small cell lung cancer (NSCLC). Although certain patients achieve significant, long-lasting responses from checkpoint blockade, the majority of patients with NSCLC do not and may be unnecessarily exposed to inadequate therapies and immune-related toxicities. Therefore, there is a critical need to identify biomarkers predictive of immunotherapy response. While tumor and immune cell expression of programmed death ligand-1 and, more recently, tumor mutational burden are used in clinical practice and may correlate with immunotherapy response in selected circumstances, neither consistently predicts an individual patient's likelihood of clinical benefit from ICI therapy. More recently, innovative approaches such as blood-based assays and combination biomarker strategies are under active investigation. This review will focus on the current role and challenges of programmed death ligand-1 and tumor mutational burden as predictive biomarkers for immunotherapy response in advanced NSCLC and explore promising novel biomarker strategies.
KW - Biomarkers
KW - PD-L1
KW - immune checkpoint inhibitors
KW - immunotherapy
KW - non-small cell lung cancer
KW - tumor mutation burden
UR - http://www.scopus.com/inward/record.url?scp=85097526227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097526227&partnerID=8YFLogxK
U2 - 10.1097/PPO.0000000000000483
DO - 10.1097/PPO.0000000000000483
M3 - Review article
C2 - 33298722
AN - SCOPUS:85097526227
SN - 1528-9117
VL - 26
SP - 507
EP - 516
JO - Cancer Journal
JF - Cancer Journal
IS - 6
ER -